Get the Stockscreener App
30.17
12.49%
3.35
Pre-market:
29.74
-0.43
-1.43%
Hims Hers Health Inc stock is traded at $30.17, with a volume of 22.83M.
It is up +12.49% in the last 24 hours and up +20.44% over the past month.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
See More
Previous Close:
$26.82
Open:
$27.88
24h Volume:
22.83M
Relative Volume:
0.84
Market Cap:
$6.98B
Revenue:
$2.35B
Net Income/Loss:
$128.37M
P/E Ratio:
57.79
EPS:
0.5221
Net Cash Flow:
$57.42M
1W Performance:
+11.04%
1M Performance:
+20.44%
6M Performance:
-16.77%
1Y Performance:
-45.62%
1-Day Range:
$27.87
$30.28
1-Week Range:
$26.02
$30.28
52-Week Range:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Name
Hims Hers Health Inc
Sector
Phone
415-851-0195
Address
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
30.17 | 6.98B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
15.77 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.07 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.69 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.95 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
549.57 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Initiated | JP Morgan | Overweight |
| Mar-10-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-10-26 | Upgrade | Citigroup | Sell → Neutral |
| Mar-09-26 | Upgrade | Needham | Hold → Buy |
| Feb-24-26 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-12-26 | Initiated | Evercore ISI | In-line |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-21-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-23-25 | Downgrade | Needham | Buy → Hold |
| Jun-04-25 | Reiterated | Needham | Buy |
| Apr-29-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-25 | Downgrade | Citigroup | Neutral → Sell |
| Jan-07-25 | Initiated | BTIG Research | Buy |
| Dec-17-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-22-24 | Initiated | Needham | Buy |
| Aug-09-24 | Downgrade | Imperial Capital | Outperform → In-line |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Apr-16-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-10-24 | Initiated | Canaccord Genuity | Buy |
| Feb-28-24 | Upgrade | Imperial Capital | In-line → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | Imperial Capital | In-line |
| Jul-28-23 | Initiated | TD Cowen | Outperform |
| Apr-11-23 | Initiated | Robert W. Baird | Neutral |
| Feb-09-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-08-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-07-22 | Initiated | Truist | Hold |
| Jul-15-22 | Initiated | SVB Leerink | Underperform |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | Deutsche Bank | Hold |
| Dec-02-21 | Initiated | Jefferies | Hold |
| Nov-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-06-21 | Initiated | BofA Securities | Neutral |
| May-20-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-21-21 | Initiated | Truist | Hold |
| Mar-09-21 | Initiated | Credit Suisse | Neutral |
| Mar-02-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Initiated | Citigroup | Neutral |
| Feb-12-21 | Initiated | Piper Sandler | Neutral |
| Feb-08-21 | Initiated | Tigress Financial | Buy |
View All
Hims Hers Health Inc Stock (HIMS) Latest News
HIMS Stock Logs Best Day In 2 Months: Bull Sees Peptides Driving Up To $19B In Annual Revenue By 2030 - Stocktwits
3 Market-Beating Stocks with Exciting Potential - The Globe and Mail
Hims & Hers (HIMS) Climbs 12.5% as Obesity Market Momentum Builds - Insider Monkey
Hims & Hers (NYSE: HIMS) director acquires 4,613 shares via RSU grants - Stock Titan
Hims & Hers (NYSE: HIMS) director converts 3,656 RSUs into common shares - Stock Titan
Hims & Hers Health (HIMS) director exercises 3,656 RSUs into common stock - Stock Titan
Hims & Hers (NYSE: HIMS) CMO exercises 4,091 RSUs, holds 187,971 shares - Stock Titan
Executive at Hims & Hers (HIMS) receives 3,656 shares from RSU vesting - Stock Titan
Hims & Hers (NYSE: HIMS) director Amoo-Gottfried Kofi Owusu files initial Form 3 - Stock Titan
Hims & Hers (NYSE: HIMS) director exercises RSUs for 14,343 shares - Stock Titan
Hims & Hers (HIMS) director gains 3,656 shares via RSU exercise - Stock Titan
Director at Hims & Hers (NYSE: HIMS) gains 13,696 shares through RSU exercises - Stock Titan
Hims & Hers (HIMS) director exercises 3,656 RSUs into Class A shares - Stock Titan
[8-K] Hims & Hers Health, Inc. Reports Material Event - Stock Titan
(HIMS) Volatility Zones as Tactical Triggers - Stock Traders Daily
HIMS Stock Set To Test A Crucial Resistance – Is Retail Expecting A Breakout? - Yahoo Finance
Hims & Hers Stock Is Surging Monday: What's Driving The Move? - Benzinga
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Hims & Hers Health (HIMS) up 15.8% since last earnings report: Can it continue? - MSN
Hims & Hers Fell 7% and Wall Street’s Price Target Now Sits Below the Stock - TIKR.com
A Look at Hims & Hers Health Inc (HIMS) After 7.1% Decline -- GF Value $38.10 vs Price $26.82 - GuruFocus
Hims & Hers at The Economist's Inaugural Economics of Obesity and Metabolic Health Summit - Hims & Hers Newsroom
Hims & Hers Health Stock Slides Friday: What's Going On? - Benzinga
Investor relations - HIMS Investor Relations
Hims & Hers Health, Inc. (HIMS) stock drops despite market gains: Important facts to note - MSN
HIMS Stock Slides Overnight: CEO Sees Healthcare Potential In Anthropic's AI Leap As Lilly, WeightWatchers Turn Up The Heat - Stocktwits
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today - Yahoo Finance
OMCL vs. HIMS: Which Stock Is the Better Value Option? - Yahoo Finance
Hims & Hers Health (HIMS) Up 15.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Hims & Hers Health (NYSE:HIMS) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
Hims & Hers (HIMS) Stock: Investors Reassess Growth Path in Digital Health Weight-Loss Push - parameter.io
Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz - The National Law Review
Why Hims & Hers Stock Jumped Today as Its Weight-Loss Bet Gets a Second Look - TechStock²
Hims & Hers Health Options Spot-On: On June 9th, 184.9K Contracts Were Traded, With 1.03 Million Open Interest - Moomoo
Hims & Hers Health Jumps 5.0% Amid Sector-Wide Rally - AlphaStreet
Hims & Hers Stock Edges Higher: What's Going On? - Benzinga
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating - Moomoo
X Square Capital LLC Raises Stake in Hims & Hers Health, Inc. $HIMS - MarketBeat
Is It Too Late to Buy Hims & Hers Health Inc (HIMS) After 3.7% R - GuruFocus
HIMS Stock Slips Despite Early Eucalyptus Buyout Close: Analyst Sees 10% Downside On GLP-1 Profit Risks - Stocktwits
Hims & Hers Health Inc (HIMS) Stock Price, Trades & News - GuruFocus
Investors heavily search Hims & Hers Health, Inc. (HIMS): Here is what you need to know - MSN
HIMS Stock Eyes 2-Week Green Streak: Analyst Sees Nearly 20% Upside On Multi-Year Opportunity In Peptides - Stocktwits
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know - Yahoo Finance
Hims & Hers Health, Inc. $HIMS Shares Sold by Capital World Investors - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Buys 43,826 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
HIMS News | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Is Investigating Hims & Hers H - The National Law Review
PPI Report April 2026: How Inflation Data Is Moving HIMS, CEG, and PLUG Stock Today - TradingKey
Hims & Hers Health Stock (HIMS) Opinions on Biotech Sector Momentum - Quiver Quantitative
Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now? - Insider Monkey
Hims Hers Health Inc Stock (HIMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
9.24%
0.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):